New drug targets Hard-to-Treat cancers with KRAS mutation
NCT ID NCT05382559
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug, ASP3082, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the best dose, either alone or combined with another drug (cetuximab). About 681 participants will receive the treatment through an IV until side effects become too severe, the cancer worsens, or they choose to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, Japan
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, Japan
-
Case Western
RECRUITINGCleveland, Ohio, 44106, United States
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Columbia University - Herbert Irving Comprehensive Cancer Center
RECRUITINGNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Denver HealthONE Drug Development Unit
RECRUITINGDenver, Colorado, 80218, United States
-
Florida Cancer Specialist
RECRUITINGLake Mary, Florida, 32746, United States
-
Florida Cancer Specialists & Research Institute Sarasota
RECRUITINGSarasota, Florida, 34232-6422, United States
-
Fudan University Shanghai Cancer Center
RECRUITINGXuhui District, Shanghai Municipality, China
-
Georgetown University Hospital
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, Japan
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, Japan
-
Kindai University Hospital
RECRUITINGSayama, Osaka, Japan
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Oncology - Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, Japan
-
Niigata Cancer Center Hospital
RECRUITINGNiigata, Niigata, Japan
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
-
Osaka International Cancer Institute
RECRUITINGOsaka, Japan
-
PanOncology Trials
RECRUITINGSan Juan, 00935, Puerto Rico
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
-
SCRI Oncology Partners
TERMINATEDNashville, Tennessee, 37203, United States
-
Shikoku Cancer Center
RECRUITINGMatsuyama, Ehime, Japan
-
Shizuoka Cancer Center
RECRUITINGSunto-gun, Shizuoka, Japan
-
Site ES34001
RECRUITINGBarcelona, Spain
-
Site ES34002
RECRUITINGMálaga, Spain
-
Site ES34003
RECRUITINGSeville, Spain
-
Site ES34004
RECRUITINGMadrid, Spain
-
Site FR33001
RECRUITINGLyon, France
-
Site FR33002
RECRUITINGBordeaux, France
-
Site FR33003
RECRUITINGLa Tronche, Grenobele, France
-
Site FR33004
RECRUITINGVillejuif, Île-de-France Region, France
-
Site FR33005
RECRUITINGLyon, France
-
Site KR82001
RECRUITINGJongno -Gu, Seoul, South Korea
-
Site KR82002
RECRUITINGSeongnam-si, Gyeonggi-do, South Korea
-
Site KR82003
RECRUITINGSeodaemun-gu, Seoul, South Korea
-
Site KR82004
RECRUITINGSongpa-gu, Seoul, South Korea
-
Site KR82005
RECRUITINGGoyang-si, Gyeonggi-do, South Korea
-
Smilow Cancer Center at Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
-
Trinity Health Ann Arbor Hospital
RECRUITINGYpsilanti, Michigan, 48197, United States
-
UCLA Santa Monica Hematology Oncology
RECRUITINGSanta Monica, California, 90404, United States
-
University of Florida, Davis Cancer Center
RECRUITINGGainesville, Florida, 32610, United States
-
University of Kansas Medical Center
RECRUITINGWestwood, Kansas, 66205, United States
-
University of Wisconsin Hospital
RECRUITINGMadison, Wisconsin, 53792, United States
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
-
Yamaguchi University Hospital
RECRUITINGUbe, Yamaguchi, Japan
Conditions
Explore the condition pages connected to this study.